The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Previously, DCGI had given approval to Cipla and Hetero to manufacture and market remdesivir. ANI had reported last month that the Central Drug Control Standard Organisation (CDCSO) office of DCGI had granted its permission to US based Gilead Sciences for marketing authorisation of its anti-viral drug remdesivir in India for ''restricted emergency use'' on hospitalised COVID-19 patients.
Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral therapy for COVID-19.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
From FLiRT To FLuQE: What To Know About The Latest Covid Variants Covid Still Kills 1,700 A Week Around World: WHO Universal Coronavirus Vaccine? New Jab Targets Even Unknown Threats Trinamool MP Summoned By Cops Over "Sniffer Dog" Claim In Rape-Murder Probe "Here For Personal Work": Hemant Soren Aide In Delhi Amid Switchover Buzz Indian-Origin Family, On Way To Daughter's College, Killed In US Car Crash CBI Begins Psychological Test Of Kolkata Rape-Murder Accused Trinamool MP Summoned By Cops Over "Sniffer Dog" Claim In Rape-Murder Probe Kareena Kapoor's "Saturday Night Date" Features This Dreamy Dessert - See Pic Track Latest News Live on NDTV.com and get news updates from India and around the world.